N‐acyl amines of docosahexaenoic acid and other n–3 polyunsatured fatty acids – from fishy endocannabinoids to potential leads
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
N–3 long‐chain polyunsaturated fatty acids (n–3 LC‐PUFAs), in particular α‐linolenic acid (18:3n‐3), eicosapentaenoic acid (EPA; 20:5n‐3) and docosahexaenoic acid (DHA; 22:6n‐3) are receiving much attention because of their presumed beneficial health effects. To explain these, a variety of mechanisms have been proposed, but their interactions with the endocannabinoid system have received relatively little attention so far. However, it has already been shown some time ago that consumption of n–3 LC‐PUFAs not only affects the synthesis of prototypic endocannabinoids like anandamide but also stimulates the formation of specific n–3 LC‐PUFA‐derived conjugates with ethanolamine, dopamine, serotonin or other amines. Some of these fatty amides show overlapping biological activities with those of typical endocannabinoids, whereas others possess distinct and sometimes largely unknown receptor affinities and other properties. The ethanolamine and dopamine conjugates of DHA have been the most investigated thus far. These mediators may provide promising new leads to the field of inflammatory and neurological disorders and for other pharmacological applications, including their use as carrier molecules for neurotransmitters to target the brain. Furthermore, combinations of n–3 LC‐PUFA‐derived fatty acid amides, their precursors and FAAH inhibitors offer possibilities to optimise their effects in health and disease. Linked Articles: This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue‐4&http://dx.doi.org/10.1111/bph.2012.167.issue‐8
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947 · cited 1×
“Anandamide (Figure 1) is a known ligand for both the cannabinoid type-1 (CB1) and CB2 receptors (receptor nomenclature follows Alexander et al., 2011) and belongs to the NAE subclass.”
BackgroundOmega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771 · cited 1×
“Benefits in humans seem to be most consistent for mortality from coronary heart disease and sudden cardiac death (Riediger et al., 2009; de Roos et al., 2009; De Caterina, 2011; Mozaffarian and Wu, 2011).”
BackgroundPolyunsaturated fatty acids and inflammatory processes: New twists in an old tale
Calder, P. C. (2009) · Biochimie · doi:10.1016/j.biochi.2009.01.008 · Cited by 721 · cited 1×
“In rodent studies, n–3 LC-PUFAs exhibit immunemodulating, anti-inflammatory and cellular protective properties (Calder, 2009; 2011).”
BackgroundBazan, N. G., Molina, M. F., & Gordon, W. C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104635 · Cited by 441 · cited 2×
“Consumption of n–3 LC-PUFAs has been associated with a variety of positive health effects (Parker et al., 2006; Carlson, 2009; Bazan et al., 2011; Calder, 2011).”
BackgroundDietary sources of omega 3 fatty acids: public health risks and benefits
Tur, J. A., Bibiloni, M. M., Sureda, A., & Pons, A. (2012) · British Journal of Nutrition · doi:10.1017/s0007114512001456 · Cited by 283
de Roos, B., Mavrommatis, Y., & Brouwer, I. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00189.x · Cited by 151 · cited 1×
“Benefits in humans seem to be most consistent for mortality from coronary heart disease and sudden cardiac death (Riediger et al., 2009; de Roos et al., 2009; De Caterina, 2011; Mozaffarian and Wu, 2011).”
BackgroundEnzymological studies on the biosynthesis of N-acylethanolamines
Ueda, N., Tsuboi, K., & Uyama, T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.08.010 · Cited by 112
Cited by
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“N-3 LC-PUFAs can also exert their effect through the modulation of the eCB system, (Meijerink et al., 2013; Bazinet and Layé, 2014; Kuda, 2017; Nadjar et al., 2017).”
BackgroundInfluentialAnti-inflammatory ω-3 endocannabinoid epoxides
McDougle, D. R., Watson, J. E., Abdeen, A. A., Adili, R., Caputo, M. P., Krapf, J. E., Johnson, R. W., Kilian, K. A., Holinstat, M., & Das, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610325114 · Cited by 172
“Importantly, the relatively higher DHEA levels and lower EPEA levels are consistent with reports in the literature (10), lending credibility to the quantitative values.”
Kalkman, H. O. (2023) · Biomedicines · doi:10.3390/biomedicines11030806 · Cited by 18
Metadata
- Authors
- Meijerink, J., Balvers, M., & Witkamp, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-05-27
- Volume
- 169
- Issue
- 4
- Pages
- 772-783
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1565819969
- Cited by
- 94
- References
- 7
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N‐acyl amines of docosahexaenoic acid and other n–3 polyunsatured fatty acids – from fishy endocannabinoids to potential leads. https://app.cochat.ai/papers/10.1111/bph.12030
- The paper
- Meijerink, J., Balvers, M., & Witkamp, R. (2013). N‐acyl amines of docosahexaenoic acid and other n–3 polyunsatured fatty acids – from fishy endocannabinoids to potential leads. British Journal of Pharmacology. https://doi.org/10.1111/bph.12030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.